Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients.
We observed the efficacy and toxicity of autologous stem cell transplantation (auto-SCT) for patients with systemic lupus erythematosus (SLE). Seventeen patients with SLE were treated with auto-SCT. No prisoners were used in the study. Peripheral blood stem cells were mobilized with cyclophosphamide (Cy) and granulocyte colony-stimulating factor. After a conditioning regimen of Cy and antithymocyte globulin, we reinfused stem cells. The probabilities of overall survival (OS) and progression-free survival (PFS) were used to assess the efficacy and adverse experiences, to detect the toxicities of the treatment. The median follow-up time was 89 months (range 33-110). Probabilities of 7-year OS and PFS were 82.4% ± 9.2% and 64.7% ± 11.6%, respectively. The principal adverse events included allergy, infection, elevation of liver enzymes, bone pain, and heart failure. Two patients died due to severe pneumonia and heart failure at 33 and 64 months after transplantation, respectively. Our 7-year follow-up results suggested that auto-SCT seemed beneficial for SLE patients.